BRAF V600E mutations for example, required for selection of combination BRAF/MEK inhibitors, occur in one-third to one-half of melanomas [8], but only in 2–4% of non-small cell lung cancer (NSCLC) patients [9], both of which are on-label FDA approved indications for BRAF/MEK inhibitors. Here, BRAF is linked to melanoma.